First Safety & Immunogenicity Data from a FIH, Placebo-controlled, Dose escalation Trial of a Recombinant Vesicular Stomatitis Virus based Lassa Fever Vaccine in Healthy Adults
11/2023
Conference Paper
Authors:
Malkin E,;
Baden, L,;
Kieh M,;
Fitz Patrick D, ;
Diemert D,;
Mutua G,;
Philiponis V,;
Zaric M,;
Hunt D,;
Barin B,;
Engelbrecht M,;
Malherbe M,;
Walker K,;
Lehrman J,;
Fast P,;
Parks C,;
Gupta SB
Secondary:
ASTMH 72nd Annual Meeting
Location: Chicago, IL
URL:
https://www.iavi.org/wp-content/uploads/2023/11/C102_ASTMH_Poster_Chicago2023.pdf
Abstract:
IAVI is developing a Lassa Fever vaccine using the attenuated chimeric VSV design (rVSVΔG-LASV-GPC) also used in the licensed Ebola Zaire vaccine, ERVEBO® (Merck). The Lassa virus (LASV) vaccine was generated by replacing the VSV surface G protein with the LASV glycoprotein complex (GPC). Vaccination with 2x105 or 2x107 pfus protected non-human primates from infection with LASV. A Phase 1 clinical trial enrolled 113 participants, 52 in a dose escalation (US) and 61 in a dose expansion (60 in Liberia, 1 in US). The dose escalation is unblinded and the dose expansion remains blinded.
